Gut Microbiota Influence in Hematological Malignancies: From Genesis to Cure.
Mireia Uribe-HerranzNela Klein-GonzálezLuis Gerardo Rodríguez-LobatoManel JuanCarlos Fernández de LarreaPublished in: International journal of molecular sciences (2021)
Hematological malignancies, including multiple myeloma, lymphoma, and leukemia, are a heterogeneous group of neoplasms that affect the blood, bone marrow, and lymph nodes. They originate from uncontrolled growth of hematopoietic and lymphoid cells from different stages in their maturation/differentiation and account for 6.5% of all cancers around the world. During the last decade, it has been proven that the gut microbiota, more specifically the gastrointestinal commensal bacteria, is implicated in the genesis and progression of many diseases. The immune-modulating effects of the human microbiota extend well beyond the gut, mostly through the small molecules they produce. This review aims to summarize the current knowledge of the role of the microbiota in modulating the immune system, its role in hematological malignancies, and its influence on different therapies for these diseases, including autologous and allogeneic stem cell transplantation, chemotherapy, and chimeric antigen receptor T cells.
Keyphrases
- bone marrow
- stem cell transplantation
- high dose
- lymph node
- multiple myeloma
- induced apoptosis
- signaling pathway
- endothelial cells
- mesenchymal stem cells
- healthcare
- cell cycle arrest
- diffuse large b cell lymphoma
- induced pluripotent stem cells
- low dose
- acute myeloid leukemia
- oxidative stress
- locally advanced
- radiation therapy
- early stage
- squamous cell carcinoma
- cell proliferation
- endoplasmic reticulum stress
- neoadjuvant chemotherapy
- young adults